Clinical trial · Observational
Multi-center MRD Registry for Inflammatory Breast Cancer
NCT06966050CI-TRIAL-00112179recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality-of-life Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- Participants will fill out a quality-of-life questionnaire and complete a MRD test.
- interventionNames
- Behavioral: Quality-of-life Questionnaire
Primary outcomes (1)
- measure
- European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire
- timeFrame
- Through study completion; an average of 1 year
- description
- European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score scale: (1-30 questions to assess the impact of participants quality of life)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female or males ≥18 years of age with the ability to understand and sign a written * Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC). * Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database. * Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer. * Participants must be English-speaking. Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.